Difference between revisions of "IEICE, et al, IEICE ESS Fundam Rev (2020), cited as Ref 51 in DOI:10.1007/s11886-020-01292-3 (Q10560)"

@@ Property / title @@
+Overview of planned or ongoing studies of drugs for the treatment of COVID-19 (English)
+Normal rank
@@ Property / First Author string @@
+IEICE
@@ Property / First Author string: IEICE / rank @@
+Normal rank
@@ Property / Publication Date @@
+Timestamp +2020-01-01T00:00:00Z
Timezone +00:00
Calendar Gregorian
Precision 1 year
Before 0
After 0
-Timestamp
++2020-01-01T00:00:00Z
-Timezone
++00:00
-Calendar
+Gregorian
-Precision
+year
 Before
 After
@@ Property / Publication Date: 2020 / rank @@
+Normal rank
@@ Property / Published In Name String @@
+IEICE ESS Fundam Rev
@@ Property / Published In Name String: IEICE ESS Fundam Rev / rank @@
+Normal rank
@@ Property / Page(s) @@
+-
@@ Property / Page(s): 177- / rank @@
+Normal rank
@@ Property / Issue @@
@@ Property / Issue: 3 / rank @@
+Normal rank
@@ Property / Volume @@
@@ Property / Volume: 13 / rank @@
+Normal rank
@@ links / sliswiki / name / links / sliswiki / name @@
+IEICE, et al, IEICE ESS Fundam Rev (2020), cited as Ref 51 in DOI:10.1007/s11886-020-01292-3

Latest revision as of 21:15, 23 June 2020

Cited in: "Cardiovascular Complications in Patients with COVID-19: Consequences of Viral Toxicities and Host Immune Response" Research article published in Curr Cardiol Rep; 2020 04 21 ; 22 (5) 32.

Language	Label	Description	Also known as
English	IEICE, et al, IEICE ESS Fundam Rev (2020), cited as Ref 51 in DOI:10.1007/s11886-020-01292-3	Cited in: "Cardiovascular Complications in Patients with COVID-19: Consequences of Viral Toxicities and Host Immune Response" Research article published in Curr Cardiol Rep; 2020 04 21 ; 22 (5) 32.